Lacosamid Beta

Lacosamide, the active ingredient in Lacosamid Beta, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency and improve neurological stability.

GNH USA supplies Lacosamid Beta as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to global hospitals, pharmacies, and clinics worldwide across multiple regulatory markets, ensuring consistent quality, a patient‑centric approach, reliable logistics, and adherence to stringent import and distribution standards.

Lacosamide is an anticonvulsant used in the management of epilepsy.

Partial‑onset seizures: adjunctive therapy to reduce seizure frequency. Focal seizures: improves overall seizure control when added to existing regimens. Epilepsy: part of combination therapy to achieve better long‑term seizure management.

Lacosamide may cause a range of adverse reactions.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Blurred vision - Somnolence

Serious or Rare Side Effects: - Prolongation of PR interval or other cardiac arrhythmias - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Hypersensitivity reactions including rash and fever - Significant elevation of liver enzymes

Safety considerations are important when prescribing Lacosamide.

Pregnancy: safety not established; weigh benefits against potential risks. Renal impairment: monitor function and consider dose adjustment. Hepatic impairment: assess liver enzymes regularly. Concomitant antiepileptics: observe for increased adverse effects. Avoid abrupt discontinuation: may precipitate increased seizure activity. Store at ambient temperature: keep in original container, protect from moisture.

Lacosamide can interact with other medicines.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine) may markedly reduce efficacy. - Co‑administration with drugs that prolong PR interval (e.g., quinidine) can increase cardiac risk.

Moderate Interactions (Monitor Closely): - Other antiepileptics such as valproate may heighten adverse effect profile. - Alcohol consumption may enhance central nervous system depression. - Concurrent use with additional sodium‑channel blockers may increase toxicity.